proportional hazard model, and a backward stepwise selection process was performed, this time at a classical α = 0.05.
Stable renal transplant recipients (RTRs) display disproportionately high rates of atherosclerotic events (AE) (1) . It is now established that both vascular inflammation and components of the immune system are involved in the pathogenesis of atherosclerosis (2) . We have already shown the importance of inflammatory and innate immunity in the pathogenesis of atherosclerosis after renal transplantation by demonstrating a correlation between the occurrence of post-transplant cardiovascular events and i) elevated circulating levels of Creactive protein (3) and ii) Toll-like receptor-4 (TLR4) Asp299Gly polymorphism (4) . Here, we analyze NOD2/CARD15 (Nucleotide Oligomerisation Domain-2/Caspase-Recruitment Domain-15, thereafter called NOD2) gene polymorphism. Three major single nucleotide polymorphisms (SNP) have been reported in NOD2 gene; SNP8, 12 and 13 alleles have been previously associated with increased susceptibility for two inflammatory diseases: Crohn's disease (5,6) and Graft-versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation (7) . This suggests that NOD2 gene polymorphism modulates pro-inflammatory diseases. NOD2 is expressed in macrophages (8, 9) and macrophages are present in atherosclerotic lesions at early stages (10) . To date, no study has evaluated the impact of NOD2 gene polymorphism on AE after transplantation. We assessed the frequency of NOD2 gene polymorphism in 182 RTRs and analyzed the relationship between such polymorphism and the development of atherosclerotic complications.
One hundred and eighty-two RTRs were enrolled in this trial. ) and GVHD (7). Several limitations should however be considered. The population studied was limited with regards to the frequency of polymorphism. However, the total number of patients was not very different from a previous publication associating NOD2 gene polymorphism and Crohn's disease occurrence (6) . Furthermore, study design leads to include patients with a low CVD risk. However, with nearly the same cohort, we had previously shown that RTRs with TLR4 Asp299Gly polymorphism exhibited a lower risk of post-transplant AE (4). This led us to discuss the respective roles of NOD2 and TLR4 in pathogen recognition. NOD2, like TLRs, belongs to a large family of proteins involved in infectious pathogen recognition (12) . As known for TLR4 at the cell membrane, intracellular NOD2 protein has been proposed to play a role in the intracytoplasmic response to bacterial cell wall products (muramyl dipeptide) and subsequent NF-B activation in macrophages (12).
In our previous study (4), RTRs with Asp299Gly TLR-4 polymorphism were less likely to experience post-transplant AE (RR=0.44), but developed more frequently severe bacterial infections (RR=1.33) and opportunistic infections (RR=3.03). These previous data together with the present data (i.e., absence of correlation between a particular NOD2 gene polymorphism and post-transplant AE occurrence) could support the idea that bacterial infections do not play a major role in the development of atherosclerosis. The relationship between infectious pathogens and atherosclerosis, originally suggested by seroepidemiologic studies (13), was also confirmed by a series of investigations demonstrating the presence of pathogens in atherosclerotic lesions (14) . On the other hand, transient prophylactic antibiotic treatment did not prevent secondary coronary syndromes (15, 16) . Therefore, the etiologic or pathogenic significance of bacterial infections in CVD remains to be determined. Finally, the functional role of NOD2 is still unclear. Most studies which implicated NOD2 in proinflammatory NF-B pathway in macrophages were performed in vitro (8, 9) . They suggested that the association of NOD2 mutations was characterized by a diminished NF-B response (8, 9) . However, the first functional study performed in vivo, using C57BL/6 mice deficient for NOD2 gene (NOD2-/-mice), did not confirm such in vitro results (17) . Macrophages from NOD2-/-mice responded normally to TLR ligands in terms of NF-B activation and inflammatory cytokine production (17) . These results suggest the absence of NOD2 implication in NF-B activation in macrophage. A more recent study using NOD2-/-mice reported that NOD2 was especially critical to regulate innate bacterial immunity in the intestinal tract (18) . This was attested by an increased susceptibility of NOD2-/-mice to intragastric infection with Listeria monocytogenes but not after intravenous or intraperitoneal injection of these bacteria (18) . NOD2 is highly expressed in crypts from the terminal ileum (18) in Paneth cells (19) . This may explain why NOD2 mutations render patients susceptible to
Crohn's diseases, a chronic inflammatory bowel disease (5,6) and GVHD (7). It is believed that the loss of gastrointestinal tract integrity, and the translocation of endogenous endotoxins into the systemic circulation, is a critical event in the initiation of GVHD (20) . Overall, NOD2
mutations may not have a major influence of vascular inflammation and this may account for the results we are reporting here. Lastly, one has to consider the potential influence of NOD2 and TLR4 ligands. TLR4 ligands are generally stronger NF-B activators than NOD2 ligands (12) . In addition to pathogens, a number of endogenous ligands (e.g., heat shock proteins known to be present in atherosclerotic lesions, extracellular matrix proteins,…) have been shown to stimulate TLR4 (12) . This again may explain why we found a relationship with TLR4 Asp299Gly polymorphism while not with NOD2 gene polymorphism.
In conclusion, NOD2 gene polymorphism is not associated with AE in RTRs population and should not be proposed to assess CVD risk in RTRs. These results underline recent data showing that bacterial infections are not involved in CVD (15, 16) and the major role of NOD2
is to control intestinal inflammation (18) . Results are expressed in Kg/m 2 for body mass index, in µmol/l for homocysteine, in years for age and for other items as number of patients and percentage in brackets. a heterozygote RTRs with a mutated NOD2 allele in either SNP8, SNP12 or SNP13 region (since no heterozygous composites or homozygous mutants were detected); b mean + SD; c 2 patients with a mutated SNP8, 2 with a mutated SNP12 and 2 with a mutated SNP13 developed AE (see also whereas  depicts the wild type allele.
